Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study by Andreas Tiede, Robert Klamroth, Rüdiger E. Scharf, Ralf U. Trappe, Katharina Holstein, Angela Huth-Kühne, Saskia Gottstein, Ulrich Geisen, Joachim Schenk, Ute Scholz, Kristina Schilling, Peter Neumeister, Wolfgang Miesbach, Daniela Manner, Richard Greil, Charis von Auer, Manuela Krause, Klaus Leimkühler, Ulrich Kalus, Jan-Malte Blumtritt, Sonja Werwitzke, Eva Budde, Armin Koch, and Paul Knöbl Blood Volume 125(7): February 12, 2015 ©2015 by American Society of Hematology
Course and outcome of immunosuppressive therapy. *All 18 patients from the 2 sites not following the IST protocol were excluded regardless of their actual therapy. **Patients not yet achieving PR but continuously improving their FVIII activity until day Andreas Tiede et al. Blood 2015;125: ©2015 by American Society of Hematology
Pathways to complete remission. Andreas Tiede et al. Blood 2015;125: ©2015 by American Society of Hematology
Adjusted time to PR and CR according to baseline FVIII activity. Andreas Tiede et al. Blood 2015;125: ©2015 by American Society of Hematology
Adjusted OS according to baseline characteristics. Andreas Tiede et al. Blood 2015;125: ©2015 by American Society of Hematology